STOCKS TELEGRAPH

Author: ST Staff

  • China SXT Pharmaceuticals, Inc. (SXTC) stock gains in Pre-Market. Let’s find out why.

    China SXT Pharmaceuticals, Inc. (SXTC) stock gains in Pre-Market. Let’s find out why.

    Shares of China SXT Pharmaceuticals, Inc. (SXTC) stock remained high in Monday’s pre-market trading session. SXTC stock was up by 33.33% to reach $2.44 a share at the time of this writing. It seems that SXTC stock was performing well in the previous trading session as it was up by 3.39% at the previous closing. But what made the stock high? Let’s deep dive to understand this bull.

    What’s happening?

    Sometimes nothing is good for everything and the same is the situation for SXTC stock. There is no particular activity by the China SXT stock, no press release today, no analysts’upgrades, or upswing targeted per share price of SXTC stock to support the rising stock price of China SXT. However it seems that sympathy play might be the driving force behind this bull as China Pharma Holdings, Inc has skyrocketed over 200% in pre-market session today in response to its fiscal year 2020 results.

    Recent Development

    Back on February 19, China SXT announced the approval of a 1 for 4 reverse split of its ordinary shares by its board of directors. These split-adjusted ordinary shares of SXTC began to trade on February 22, 2021. In connection with this announcement, shareholders of China SXT stock received one new share for every four shares which they owned. As of February 18, China SXT had approximately 62,057,584 outstanding ordinary shares which reduced to 15,514,396 approximately after the reverse split.

    Here is what you need to know about China SXT Pharmaceuticals, Inc.

    • China SXT is mainly operating in the fields of research, development, manufacturing, and marketing of its traditional Chine medicine piece tablets in the Republic of China. SXTC stock has a current market cap of 28.391M.
    • China SXT is a well-established company that provided services to 116 pharmaceutical companies, served 56 pharmacies and 76 hospitals as of May 2020.
    • Feng Zhou, a graduate of Pla National Defense University, is the Chief Executive Officer of the SXTC.
    • China SXT Pharmaceuticals was founded in 2005 and its headquarters are in Taizhou, China.

    Conclusion

    Things are going in favor of SXTC stock as far as market sentiment is concerned but no one knows how long this trend will continue in the future. There is no update about the earnings report so far by the China SXT. In a nutshell, investors should keep an eye on this stock.

  • CS stock declines in the pre-market trading. Let’s find out why?

    CS stock declines in the pre-market trading. Let’s find out why?

    Credit Suisse Group Inc. (CS) stock plunged by 2.57% in the last trading closed while the CS keeps on declining by 10.88% during the pre-market trading as well after Nomura Holdings Inc. and Credit Suisse Group AG announced that they face relatively huge losses as some of the world’s biggest banks count their exposure to inaccurate bets through Archegos Capital Management. Credit Suisse is a leading financial services company in the world. Credit Suisse’s key strengths, such as its role as a leading wealth manager, specialist investment banking expertise, and strong presence in our home market of Switzerland, are the pillars of their strategy.

    What is happening?

    After Archegos failed to reach margin calls last week, lenders to Bill Hwang’s New York-based family office have been rushing to manage the repercussions. The enforced liquidation of more than $20 billion in Archegos-related positions has wracked stocks ranging from Baidu to ViacomCBS shedding light on the murky world of leveraged trading strategies facilitated by some of the biggest names on Wall Street.

    Although the chaos has had a minimal effect on wider financial markets so far, banks and people familiar with the situation have suggested that the unraveling of Archegos-related bets could take longer. According to a statement from the bank that didn’t mention Archegos by name, Credit Suisse and other lenders were still exiting positions on Monday. Some people who are well aware of the situation mentioned that Morgan Stanley was buying a huge block of ViacomCBS shares on Sunday.

    Now what?

    While it is too early to estimate the size of the loss, Credit Suisse believes it will be important and material to CS’s first-quarter results. On Monday CS shares, which are also engaged in a scandal involving the collapse of Lex Greensill’s trade finance empire, dropped as much as 14%.

  • CRH stock rises during pre-market trading. Here’s to know why?

    CRH stock rises during pre-market trading. Here’s to know why?

    CRH plc Inc. (CRH) stock gained by 1.87% in the last trading close whereas the CRH stock rises by 20.72% during pre-market trading session. CRH plc has not given any news through a press release but quite recently on March 25, it was being announced that Moody’s Investors Service has today declared CRH plc’s Baa1 long term issuer rating. With headquarters in Dublin, Ireland, CRH plc is an Irish multinational company of diversified building materials businesses that produce and supply a broad array of products for the construction industry.

    What is happening?

    On March 25, The Baa1 long-term issuer rating of CRH plc has been verified by Moody’s Investors Service. At the same time, the agency confirmed the group’s senior unsecured EMTN program rating of (P) Baa1 and supported commercial paper program rating of P-2. The outlook for all ratings is unchanged. Also the Assistant Vice President of Moody’s Vitali Morgovski said that, CRH track record of preserving solid credit metrics and consistently positive free cash flow production is reflected in today’s rating action. Despite the pandemic situation, CRH’s success in 2020 was strong, and it is expected to remain strong as the economy recovers in the next 12-18 months.

    CRH strong cash balance and continuing positive FCF generation give it plenty of room to explore inorganic opportunities without endangering its current ranking. The rating of CRH is largely based on the group’s:

    • Good product Diversification.
    • The strong vertical integration, with a greater exposure to more durable and less capital-intensive light-side building materials than its cement competitors.
    • Strong liquidity profile.
    • Regional diversification, despite the fact that CRH is more concentrated on established developed markets in Europe and North America than its competitors.
    • Credit indicators, which held up well through the downturn in 2009-11 and will continue to do so in 2020.

    This is probably due to which the CRH stock price is rising since the investors are liking to hold on CRH stock because of its robust performance even in the pandemic.

    Constraints faced by CRH’s rating

    Given below are the problems that were being faced by CRH:

    • The unsustainability of construction end-markets.
    • Economic development is still being hampered by continued lockdowns, and some construction sub-segments, such as non-residential construction, are seeing weaker demand outlooks.
    • M&A-related event risk, considering CRH’s history of multibillion-dollar acquisitions, notwithstanding last year’s relatively low activity on that front.
    • Increasing shareholder salaries through higher dividends and share buybacks.

  • GOSS stock plunged 12% in after-hours trading. Why is it so?

    Gossamer Bio Inc. (GOSS) stock plunged 12.43%in after-hours trading on Friday while there is no recent news hitting the media regarding the rise in GOSS stock price. Gossamer has recently announced its financial results for fourth quarter and full year 2020 that we will discuss below to get an idea about Gossamer’s progress so far. Gossamer Bio is a biopharmaceutical company based on identifying, acquiring, improving, and commercializing therapeutics to deal with diseases related to immunology, inflammation, and oncology.

    Fourth Quarter and full year financial results

    GOSS released its financial results for full year and fourth quarter 2020 on February 25. Given below is the summary of announced financial results:

    • GOSS has generated the cash and cash equivalents and marketable securities as $512.6 million for the year ended on December 31, 2020. Because of this amount in addition with access to GOSS debt facility, Gossamer is expecting that this will be enough to finance the operating and capital expenditures into the second half of 2023.
    • For the fourth quarter 2020, the research and development expenses were $38.9 million whereas for the full year the values were $160.9 million compared to $42.6 million and $143.4 million for the fourth quarter and full year 2019, respectively. The rise the R&D expenses is due to the increase in expenses for GB004, seralutinib, GB1275 and preclinical programs.
    • GOSS General and administrative expenses for the fourth quarter were $15.9 million as compared to $11.6 million for the fourth quarter 2019. Similarly the G&A expenses also increased for the full year 2020 recorded as $49.7 million as compared to $39.1 million for the year 2019 because of the increase in stock based compensation costs as well as a rise in personnel-related costs.
    • Lastly the Net loss faced by GOSS in the fourth quarter of 2020 was $64.6 million compared to $54.7 million. While for the full year 2020, the net loss was $243.4 million comparatively higher than the net loss of full year 2019 which was $180.3 million.

    Important Past Event

    On February 4, GOSS announced that the management is planning to organize a conference call and webcast for investors and analysts in order to talk about GB004, the oral HIF-1α stabilizer that is for the treatment of inflammatory bowel disease and also ulcerative colitis. The event was supposed to happen on Thursday, February 18, 2021, but GOSS did not release the details about the event as of whether it happened or not therefore it will be difficult to say anything about further proceedings.

  • Here is why TBLT Stock Plummeted in Friday’s extending trading session

    Here is why TBLT Stock Plummeted in Friday’s extending trading session

    The TBLT stock sunk 20.43% on Friday, March 26, 2021, after the announcement of its financial results. Let’s have a brief look at TBLT’s financial results for the fiscal year ended December 31, 2020.

    Financial Highlights for 2020

    • TBLT reported revenues of $39.4 million for the year 2020, compared to $19 million for the previous year.
    • It suffered a net loss of $18.6 million, or $0.68 per share for the reported year, compared with $6.4 million, or $2.08 per share in fiscal 2019.
    • TBLT has managed to increase its gross profit to $14.7 million, compared with $5.6 million in 2019.

    TBLT regained compliance with Nasdaq’s listing requirements.

    On February 9, 2021, TBLT announced that it has regained compliance with the minimum bid price requirement outlined in Rule 5550(a)(2) of the Nasdaq Listing Rules.

    Nasdaq informed TBLT on July 24, 2020, that the closing bid price per share had been below $1.00 for a period of 30 consecutive business days and that the Company did not meet the Minimum Bid Price Requirement. The TBLT gave 180 days extension on January 21, 2021, to meet Nasdaq’s requirements for listing qualification.

    About TBLT

    TBLT was founded in 2012 and its headquarter is in California, United States. The company manufacture and distribute the advanced product design mostly focused on tools and other accessories for the professional and do-it-yourself construction industries.

    Conclusion

    Though the recent financial results showing a revenue increase it suffered a huge net loss compared with the previous year which results in its stock value plummeting on Friday.

  • CPHI Stock Announces Incredible Fiscal Year For 2020

    China Pharma Holdings, Inc. (CPHI) a New York stock exchange-listed pharmaceutical company that produces and advertises a diverse portfolio of products, focuses on diseases with high transmission rates and high mortality rates in China. The company’s efficient business model driven by market demand combined with a very large distribution network across all major cities in China is anticipated to generate massive revenue as the new GMP-certified products release. CPHI stock has also made a subsidiary company known as, Hainan Helpson Medical & Biotechnology Co., located in Haikou city, which specializes in medicine production.

    The company collected net revenue of $10.9M due to foreign trading of COVID-19 testers as market demand for covid related products increased and popped their gross margin from 13.6% in the fiscal year 2019 to 18% in the fiscal year 2020. A Net loss of $2.9 million took place in 2020 against a staggering $20.7 million loss in the fiscal year 2019.

    CPHI Business model variation 

    Ms. Zhilin Li, China Pharma’s Chairman, and CEO stated, “The outbreak of COVID-19 early in this year has created a substantial, negative impact on sales of pharmaceutical companies, including ours. Many people try to avoid going to hospitals for fear of cross-contamination or potential infection” However the company amended its business model to a more consumer-centric approach and started producing products related to Coronavirus which had huge market demand and surged their revenue substantially.

    However, due to unpredicted variation in product demand, market competitiveness; slow-progressing economy, and low levels of RnD, CPHI stock has accumulated a loss of a collective $23M in the past two years and has the company striving for better financial results.

  • MKD Stock Signs A Cooperating Agreement With Anhui Shilian Special Solvent Co.Ltd, China’s Largest Specialty Solvent Producer

    MKD Stock Signs A Cooperating Agreement With Anhui Shilian Special Solvent Co.Ltd, China’s Largest Specialty Solvent Producer

    MKD Stock, China’s leading technology-based platform has signed up for a joint venture with Anhui Shilian Special Solvent Co. Ltd, one of the most significant manufacturers in China’s liquor market, producing high-quality specialty solvents. The two parties are expected to increase cooperation to develop high-purity solvent series as an attempt to expand market share in the food and beverage industry and provide industry users with more diversified and high-quality products and services.

    MKD plans to sell products via e-commerce through an independent internet channel and provide a digital management system. This will optimize the distribution network, it will also enhance Anhui Shilian’s market share in the industry, hence giving their target customers a more efficient and effective experience.

     

    About The Contract Regulations Between MKD And Anhui Shilian Special Solvent Co. Ltd

    In accordance to the contract, MKD will have a key role in supplying chemical solvents, biological reagents, laboratory consumables, as well as adequate machinery and equipment for Gujing and the companies linked to it, which also specialize in the production of high purity solvents.

    MKD will produce nearly 2 million stock-keeping units (SKUs) that Gujing ordered from its 21 professional, local and outsourced laboratory brands and manufacturers.

    Gujing’s research capabilities in the liquor industry will be further enhanced by MKD’s ability to provide an e-commerce service platform and procurement services that include an immense variety of high-quality solvents, in accordance with the standards of internationally recognized laboratories

    Conclusion

    MKD has a detailed coverage that entails distribution network and e-commerce. This joint venture will help enhance Anhui capabilities in the high-purity solvent industry and help to provide diversified services bringing digital upgrades to the industry.

  • Aeterna Zentaris Inc. (AEZS) Releases 2020 Financial Earnings

    Aeterna Zentaris Inc. (AEZS) is a biopharmaceutical company that specializes in manufacturing and distributing therapeutics and tests used for medical diagnosis. The company is also expanding its current development pipeline and clinical trials of macimorelin- which will be used in the diagnosis of a growth hormone deficiency, an area without adequate medical need.

    The company Regained agreement with minimum bid price policy for continued listing on Nasdaq and AEZS common shares had a close bought deal for gross capital exceeding $34 million. The company also received $20M in capital from share dilution and using warrants.

    AEZS Plans For Pipeline Expansion

    AEZS continued to execute its pipeline expansion developing its pre-clinical programs via several licensing agreements with European universities. The Company started an official license agreement with Julius-Maximilians-University of Wuerzburg, Germany, having international patent and rights to produce and advertise, extremely distinct immunosuppressive protein therapeutics expecting treatment for Neuromyelitis Optica spectrum disorder, which has an unmet medical need.

    The company also amended its current license with Novo Nordisk for manufacturing Macrilen to penetrate Canadian and American markets.  AEZS is currently meeting the concerned medical authorities for confirmation of preclinical data required to advance into human clinical trials.

    Production of a Potential Oral Bacterial Vaccine For COVID-19

    AEZS has announced to be part of an exclusive international sub-licensable contract for a COVID 19 vaccine which is present in an initial development phase at the Julius-Maximilians-University. The company has a research agreement and is already looking for a pre-clinical trial for the potential vaccine.

    The vaccine uses the salmonella strain as an orally active live-attenuated bacteria to prevent COVID 19 improving the immune response against mutated viruses.

    Conclusion

    AEZS is in the lucrative field of biopharmaceuticals and is keen on research for vaccines of COVID and diseases with unmet medical needs. Savvy financial moves like share dilution and close bought deals have given the company a market capitalization of a staggering $135M and is anticipating a surge in revenue if the covid 19 vaccines produce efficient results.

  • Four Seasons Education Inc. (FEDU) rises in current market. Why is it so?

    Four Seasons Education Inc. (FEDU) rises in current market. Why is it so?

    Four Seasons Education Inc. (FEDU) rises by 33.58% in the current market trading session. There is no recent news or press release available regarding this rise in FEDU stock price. Four Seasons Education is a well-known educational company that works to provide extensive after-school education services, with an emphasis on high-quality of math education. The Company offers educational services mainly focusing on basic-level math, but it has recently grown to include other subjects, such as physics, chemistry, and languages, as well as other grade levels, such as kindergarten and middle school.

    Recent Developments

    On January 12, 2021, Four Seasons Education reported its third-quarter fiscal 2021 financial results. From these results, we can get a little bit of idea about what is happening in FEDU, lately. Given below is an overview of financial results:

    • The revenue generated by Four Season Education in the third quarter was RMB67.6 million compared to RMB103.5 million for the third quarter fiscal 2020.
    • The Gross profit calculated by FEDU for the third quarter was RMB25.2 million while it was RMB53.0 million for the same period of last year.
    • Lastly the net loss was $RMB 8.8 million whereas the net loss for FEDU in the previous year’s third quarter was RMB11.3 million.

    So what?

    Due to the ongoing pandemic situation, the education business has been affected a lot. The learning centers were 49 in total, as of November 30, 2020 while at the same time period in 2019 the learning centers were 55. Whereas the number of students enrolled was 53,493 as compared to 67,714 during the same period in 2019.Also, FEDU mentioned in the report that they were expecting revenue of RMB64 million in the fourth quarter the report of which has not been given yet.

  • Why Tencent Music Entertainment Group (TME) stock is falling today?

    Why Tencent Music Entertainment Group (TME) stock is falling today?

    Shares of Tencent Music Entertainment Group (TME) were low today amid the spread of a proposal by the Chinese government to establish a joint venture with local tech to access the consumer data. TME stock price saw a downtrend of 8.89% to reach $18.55 a share at the time of this writing. AT the previous trading session, TME stock was red with a 12.17% drop. Let’s deep dive to explore more the current scenarios.

    State-backed Company

    The Chinese government is planning to create a state-backed company along with its biggest eCommerce and online payment platforms in order to access the lucrative data of the consumers to tighten the grip over their activities on the internet. This step will help regulators in introducing regulatory laws in the tech world in the future. Companies like Alibaba Group Holding Ltd, ByteDance Ltd., and Meituan and Tencent Holdings Ltd were initially encouraged to support the government in this regard by sharing the consumer data from e-commerce to social media platforms.

    Financial View of TME stock

    On  March 22, 2021, TME stock announced its fourth quarter and full-year unaudited results of 2020 the summary of which is given below

    Total Revenues surged by 14.3%YoY to reach RMB8.34 billion in the fourth quarter of 2020. Online Music service revenues showed 29% growth in the fourth quarter of 2020  as compared to the same quarter of 2019 while revenues from subscriptions surged by 41.9% to reach RMB1.58 billion in the last three months of 2020. Overall revenue of the year 2020 totaled RMB29.15 billion representing a 14.6% increase over the year.TME generated  RMB25.43 billion in 2019.

    Conclusion

    Things are gloomy for TME stock as far as market sentiment is concerned. Tencent Music’s recent earnings report shows that TME stock has progressed over the year as it met the expectations of analysts for both sales and earnings. We saw a couple of fluctuations in the TME stock price this week as it soared after its earnings results and then happened to be down might be due to analyst downgrade and still continuing the bearish trend.